Home・Elenco Azioni・Xencor Inc

Xencor Inc

Chiusa

SettoreSettore sanitario

19.36 -0.62

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

18.87

Massimo

19.85

Metriche Chiave
By Trading Economics
Entrata	-214M -129M
Vendite	-24M 4.5M
EPS	-1.71
Margine di Profitto	-2,854.65
Dipendenti	260
EBITDA	-127M -121M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+23.4% upside

Dividendi
By Acuity
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	404M 1.4B
Apertura precedente	19.98
Chiusura precedente	19.36

Notizie sul Sentiment di mercato

By Acuity

50%

163 / 340 Classifica in Healthcare

Xencor Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 lug 2026, 19:11 UTC

Xencor Inc shares are lower in Friday's session, reflecting broader market trends. No specific news was identified to explain the price movement.

22 lug 2026, 20:06 UTC

Xencor Inc shares are lower today, retracing from an earlier peak. Broader market sentiment is affected by uncertainty ahead of the Federal Reserve meeting.

21 lug 2026, 19:02 UTC

Social Media

Xencor Inc. shares reached a new 52-week high, driven by developments in RCC related to ENPP3 and immuno-oncology efforts involving TL1A.

20 lug 2026, 19:41 UTC

Social Media

Xencor Inc's shares are higher as clinical results are accepted for presentation at the ESMO conference, with a Phase 3 trial planned for 2027.

Confronto tra pari

Modifica del prezzo

Xencor Inc Previsione

Obiettivo di Prezzo

By TipRanks

23.4% in crescita

Previsioni per 12 mesi

Media 24.1 USD 23.4%

Alto 38 USD

Basso 13 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Xencor Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Xencor Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

163 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.